CGEM
Cullinan Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$15.45
−0.71%Oct 8, 2026, 11:00 UTC
Cullinan Therapeutics, Inc. announced that the first patient was dosed in its Phase 2 study of CLN-049 for relapsed or refractory acute myeloid leukemia.
Source:Sep 24, 2026, 11:00 UTC
Cullinan Therapeutics outlined fourth quarter 2026 milestones for its immunology and oncology T cell engager pipeline, including multi-dose data for velinotamig in SLE at ACR Convergence 2026 in November, CLN-978 data in SLE, RA and Sjögren's disease in December, and updated CLN-049 Phase 1 data in December.
Source:Sep 10, 2026, 17:00 UTC
Cullinan Therapeutics announced it will host a virtual analyst and investor event to showcase Phase 3 REZILIENT3 data for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC, to be presented at the IASLC 2026 World Conference on Lung Cancer on September 13, 2026.
Aug 13, 2026, 15:21 UTC
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced positive Phase 3 trial data for zipalertinib as a first-line treatment for certain lung cancer patients.
Source:Aug 6, 2026, 11:00 UTC
Cullinan Therapeutics announced that it will present multi-dose regimen data for CLN-978 in rheumatoid arthritis in Q3 2026 and in systemic lupus erythematosus in Q4 2026, and will begin Phase 2 expansion studies in early 2027.
Source:Aug 6, 2026, 00:00 UTC
Cullinan Therapeutics reported a net loss of $53.7 million for Q2 2026, with cash and investments of $356.0 million as of June 30, 2026.
Jul 28, 2026, 11:00 UTC
Cullinan Therapeutics received positive feedback from the FDA after an End-of-Phase 1 meeting for CLN-049, advancing the program to a potentially registrational Phase 2 study in acute myeloid leukemia.
Source:Jun 6, 2026, 09:15 UTC
Cullinan Therapeutics presented initial clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress.
Source: